Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics
Maryam Ahmadi, Christine J. Bryson, Edward A. Cloake, Katie Welch, Vasco Filipe, Stefan Romeijn, Andrea Hawe, Wim Jiskoot, Matthew P. Baker, Mark H. Fogg. Pharmaceutical Research, An Official Journal of the American Association of Pharmaceutical Scientists, ISSN 0724-8741, Pharm Res, DOI 10.1007/s11095-014-1541-x Abstract PURPOSE: Determine the effect of minute quantities of sub-visible aggregates on the in vitro immunogenicity of clinically […]... Read more
Drug Discovery Tutorial: Detection and Reduction of Immunogenicity
Drug Discovery Tutorial: Detection and Reduction of Immunogenicity This article discusses how early removal of T-cell epitopes reduces risk of adverse immune responses in patients and how technologies such as Composite Human Antibodies can achieve this. Ji-won Choi. GEN; March 2015.... Read more
Conjugation of PolyPEG to Interferon Alpha Extends Serum Half-Life while Maintaining Low Viscosity of the Conjugate
B. Podobnik, B. Helk, V. Smilović, Š. Škrajnar, K. Fidler, S. Jevševar, A. Godwin, and P. Williams. Bioconjugate Chem., 2015, 26 (3), pp 452–459 Abstract The covalent attachment of poly(ethylene glycol) (PEG) to therapeutic proteins is a commonly used approach for extending in vivo half-lives. A potential limitation of this PEGylation strategy is the adverse effect […]... Read more
Technology Advances Enable Creation of Better ADCs
Technology Advances Enable Creation of Better ADCs Waterman. BioProcess International. 2014; 12(9)s: 37-40... Read more
A New Reagent for Stable Thiol-Specific Conjugation
George Badescu, Penny Bryant, Julia Swierkosz, Farzad Khayrzad, Estera Pawlisz, Monika Farys, Yuehua Cong, Maurizio Muroni, Norbert Rumpf, Steve Brocchini, and Antony Godwin; Bioconjugate Chem., 2014, 25 (3), pp 460–469 Abstract Many clinically used protein therapeutics are modified to increase their efficacy. Example modifications include the conjugation of cytotoxic drugs to monoclonal antibodies or poly(ethylene glycol) […]... Read more
Abzena CEO, John Burt interviewed for the Cambridge Business magazine
Abzena CEO, John Burt interviewed for the Cambridge Business magazine Chief executive Dr John Burt talks to Jenny Chapman from the Cambridge Business magazine about the unusual structure of the business and its tremendous technology. Find the article on page 19 entitled “Abzena’s fabulous float and the comeback kid that is biotech”. Burt. Cambridge Business. November 2014.... Read more
Assessing Immunogenicity Using Ex Vivo T cell Assays
Assessing Immunogenicity Using Ex Vivo T cell Assays This article discusses Antitope’s developed highly sensitive ex vivo T cell assay technology that can detect T cell responses against T cell epitopes in therapeutic proteins. These assays can be used to select non-immunogenic lead proteins as well as support the optimisation of leads by engineering out […]... Read more
Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
George Badescu, Penny Bryant, Matthew Bird, Korinna Henseleit, Julia Swierkosz, Vimal Parekh, Rita Tommasi, Estera Pawlisz, Kosma Jurlewicz, Monika Farys, Nicolas Camper, XiaoBo Sheng, Martin Fisher, Ruslan Grygorash, Andrew Kyle, Amrita Abhilash, Mark Frigerio, Jeff Edwards, and Antony Godwin. Bioconjugate Chem., 2014, 25 (6), pp 1124–1136 Abstract To improve both the homogeneity and the stability of […]... Read more
Bridging the Conjugation Gap: Maintaining Disulfide Bridges Leads to Improved Homogeneity and Stability for ADCs
Antony Godwin. Genetic Engineering & Biotechnology News. January 2013, 33(3): 20-21. doi:10.1089/gen.33.3.10. A new wave of antibody-target anticancer therapies is showing great clinical promise, with the potential to transform cancer treatment. These antibody-durg conjugates (ADCs) are multicomponent systems that combine recombinant and chemical technologies to deliver a highly potent cytotoxic drug to a tumor thereby […]... Read more
Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics
Baker M, Carr F. Curr Drug Saf. 2010 Oct;5(4):308-13. Abstract Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the […]... Read more